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Abstract
Title: A Survey Assessing the Contributing Factors to Substance Abuse
Treatment in U.S. Corrections Settings
Authors: Michael Soule, Frederick Altice (Section if Infectious Diseases,
Department of Internal Medicine, Yale University School of Medicine, New
Haven, CT)
Abstract: In light of the dramatic rise in incarceration due to the “War on Drugs,”
we explored the contributing factors to substance abuse treatment (SAT)
programming – in particular, evidence-based treatments like medication assisted
therapy (MAT) – implementation in United States correctional settings (including
jails, prisons, and community corrections facilities). We hypothesized that current
funding availability would be the primary factor preventing and contributing to
program implementation, but further hypothesized that an array of secondary
factors such as overcrowding, geographic location, facility type, and attitudes and
knowledge about MAT would also play a role. We mailed a survey to an enriched
sample of 225 correctional units’ administrators (57 jails, 129 prisons, and 40
community corrections units) across the country, selecting for units previously
identified by a national survey as being located in areas particularly likely to be
affected by high rates of drug-related crime. 54.9% responded. As was
previously recognized, a majority (81.5%) of units reported some form of SAT
programming, but low levels of MAT implementation were identified (16.1%, a
majority of which was methadone). Funding cuts were identified as the most
pressing barrier to future treatment implementation as well as the greatest

contributor to recent SAT program closure. However, Other factors, such as
offender need and recidivism reduction were identified as factors contributing to
program opening. Some geographic trends were noted, with respondents from
the Southeastern US reporting less MAT availability as well as less willingness to
implement it. Some differences were also noted across facility types, with jails
much more likely than either prisons or community corrections to implement
MAT. In a multivariate regression model, respondent score on a scale measuring
attitudes towards methadone programming was the only factor significantly
associated with current implementation of MAT. Both attitudes score and recent
increases in SAT-specific budget were significantly associated with a willingness
to consider implementing MAT in the future. We concluded that the bias towards
counseling-based programming seen in our study was not unique and, taken
along with the result that attitudes were more important than funding for current
MAT implementation, this indicated that facility administrators’ comfort with a
program was the most important factor and that funding would be allocated
accordingly. In the interest of expanding evidence-based SAT programming in
this high-need population, we suggest that a targeted education campaign may
be useful in improving attitudes, and that pilot programs to show proof of concept
in regions that lack MAT (Southeast and Southwest) would likewise be beneficial.
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Introduction

Overview
This work sits at the intersection of public policy and addiction medicine,
with implications for future programming and policy surrounding treatment of
substance abuse disorders in the United States. Individuals with substance
abuse disorders have been the subject of a large public debate over the last
several decades and many agree that the ways in which we as a society are
attempting to manage the problems that arise around substance abuse are not
appropriate. In large part, the United States has been engaged in a “war on
drugs,” both within and outside of our national borders, which encompasses
military operations in foreign countries, international policy, and also the
imprisonment of hundreds of thousands of American citizens. Nationwide,
governments state and federal have chosen punitive over treatment measures as
the intervention of choice to try to solve the problem of drug abuse and
dependence in America.
This work seeks to illuminate the interaction between politics and drug
abuse treatment and with an eye towards policy recommendation. Broadly
speaking, the available evidence strongly indicates that treatment, not
incarceration, is the optimal policy solution to the problem of American drug
abuse and addiction. Key to this argument is regarding the incarceration of drug
users for such crimes as possession of drugs or paraphernalia and the choice to
punish and not treat as clear policy choices. We encourage the reader also to
consider drug abuse treatment as a viable, evidence-supported alternative.
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Experts in the field feel so strongly about this that they call “Punishment alone…
a futile and ineffective response to drug abuse.”(1)
This paper seeks to provide two things: a dense, thorough introduction to
this complex arena and the results of our study on the barriers to the
implementation of this optimal solution. In the introductory section, terminology
will be established, neurobiology briefly presented, and prevalence of substance
abuse disorders presented. With that background, an overview of treatment
methods will then be discussed. Then, the presence of the drug-involved
offender in the correctional system will be explored, as will several of the most
important factors associated with the incarceration of drug-abusing individuals.
Then, several solutions to this complex issue (including public policy and
academic pilot models) will be presented. This paper will then present the details
of our study methods, results, and pertinent discussion.
Substance Abuse and Dependence
Until recent years, substance use was considered a social harm and
associated with deficits in personality and individual fortitude. Over the past few
decades, there has become increasing evidence for the complex interplay
between biology, behavior, genetics and environment underlying substance
dependence and abuse. This has lead to the current understanding that
substance use disorders are a chronic, relapsing - remitting disease with
components of chemical dependence as well as habitual patterns and social
structures surrounding obtaining money for drugs, obtaining drugs, and using
drugs. There are now well-established diagnostic criteria defining substance
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dependence and substance abuse as distinct, both of which are clinical
diagnoses, met by assessing symptoms and signs over a 12-month period.
Substance dependence is a complex interplay between physiology and
psychology. Physiologic dependence is a physical requirement for stimulation of
an individual’s receptors by drug molecules. When drug molecules are not
available, a withdrawal state ensues. Part of the spectrum of substance
dependence often includes substance use with the aim of abrogating withdrawal
symptoms. Drugs that produce dependence often also produce tolerance which
is defined as an individual increasing dose to maintain desired effect. Aspects of
dependence are observable in drugs of abuse as well as in medications used for
common medical conditions including hypertension.
The DSM-IV further defines substance dependence as including features
of psychological dependence: compulsive, stereotyped behaviors of drug
seeking, procurement, and use, often at the cost of other social, work, or selfcare obligations. Some drugs of abuse are traditionally thought to be
psychologically but not physiologically dependence-forming (e.g. marijuana,
hallucinogens).(2)
Substance abuse is defined as the detrimental pursuit and use of drugs of
abuse despite negative effects on the user’s livelihood, health, personal
relationships, and overall quality of life. Involvement with the legal system is
common as is a chaotic and highly risky lifestyle. The detrimental effects of
substance abuse on society include lost productivity, criminal involvement and
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the associated law enforcement- and incarceration-related costs, property
damage, and health care related costs.(3)
Recent data from the Substance Abuse and Mental Health Services
Administration indicate that large portions of the population meet criteria for
substance abuse and dependence and may suffer from the detrimental effects of
substance abuse: 8.7% of the U.S. population over the age of 12 were classified
with substance abuse or dependence by DSM-IV criteria with fully 21.5%
reporting “last month drug use” in the age bracket 12-25 years old.(4) These
statistics have been relatively stable over the last 3 years. The estimated cost of
substance abuse on society in dollar estimates is huge: the National Institute on
Drug Abuse (NIDA) projected $181 billon in costs related to illicit substance
abuse and $235 billion in costs related to alcohol abuse.(5) Understanding how
best to treat substance abuse and lower these social and individual costs is thus
a clear priority.

Biology of Substance Abuse and its Treatments
To best understand substance abuse treatment, there are a few essential
neurobiological points that should be considered. Understanding the ways in
which drugs of abuse cause such deep-rooted shifts in individuals is of primary
importance. Dopamine-driven reward pathways are known to be involved in the
initiation and continuation of substance abuse and dependence. In brief, these
are the pathways that normally orient us towards life-preserving behaviors (i.e.
food, relationships).(1) These pathways are differentially over-stimulated with
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drugs of abuse and the importance of the drug begins to exceed the importance
of life-sustaining basics.(6) An essential part of substance abuse treatment is
addressing the re-orientation of these neurobiochemical pathways towards nondrug rewards. This often takes time and repeated efforts, contributing to high
“failure” rates when individual treatment episodes are considered in isolation.
One of the hallmarks of physiologic dependence is an alteration of
receptor chemistry. As an addictive substance persists in the central nervous
system of an individual, the receptors to which the substance binds tend to alter
their density to accommodate the over-stimulated state that prolonged use incites
and tolerance develops. Invariably, the receptors stimulated by drugs of abuse
play roles in normal CNS functioning. This often means that to maintain a feeling
of “normalcy,” a substance dependent individual must maintain a baseline level
of substance intake. Without this maintenance of drug levels, an addicted
individual goes through “withdrawal” – a syndrome of symptoms that varies
between drugs of abuse resulting from a lack of receptor occupancy. These
alterations contribute to the behavior of drug-seeking as well as the desperation
that can accompany it.
Evidence supports treatment of substance use disorders that focuses on
behavioral and habitual change (through counseling or various kinds of
psychotherapy) as well as maintaining normal neurochemical levels (may include
pharmacotherapy with receptor agonists, partial agonists, or antagonists). As
with other mental illnesses, the evidence supports a combination of the
medically- and cognitively-oriented therapies.(7) Pharmacological treatments of
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substance abuse disorders are limited in scope, but several are highly effective.
The most effective medical treatments are for opioid abuse of which methadone
and buprenorphine have the most evidential support.(8) Alcohol abuse and
dependence can be treated with a number of pharmacologic agents.
Varencycline and nicotine replacement are evidence-based medication-assisted
therapies for nicotine dependence. Unfortunately, at this time there are no
evidence-based medication treatments available for other drugs of abuse,
including cocaine, amphetamines and club drugs.(7)

Pharmacologic Treatment of Opioid Dependence
The most extensive body of evidence exists for opioid dependence
treatment. The two main pharmacologic agents available both act as agonists on
the same receptors that opioids of abuse act. Methadone has been available in
the United States since 1947 and methadone maintenance (MMT) to treat opiate
addition has been in widespread use since the 1970s. In heroin or other opioid
addiction (e.g., prescription opioids), the addicted individual’s opiate receptors
down-regulate and in order to maintain normal function, the presence of an
opiate agonist is required. Methadone is a full mu opioid receptor agonist with
greater affinity for the receptor than heroin. A maintenance dose ideally provides
an individual with enough receptor occupancy to function normally without
symptoms of opiate withdrawal (i.e. agitation, insomnia, nausea, diarrhea). Its
oral dosing also prevents injection-related risk of disease transmission.
Methadone can be injected, however, if taken outside of the clinic context.
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There is a surfeit of evidence supporting the use of methadone in the
treatment of opioid addiction, (9, 10) but notably, a 2000 JAMA study showed
that MMT was significantly superior to detox and psychosocial support in terms of
maintaining clients in treatment and in the longer term (6-12 months), resulted in
fewer heroin use days.(11) Methadone itself is also relatively cheap. The
drawbacks of methadone are numerous, however: because it is a partial agonist,
there is both a danger of overdose and of diversion and abuse associated with it;
these features require methadone to be distributed in highly regulated settings
and with federal regulations on its use, both of which are costly measures.
Buprenorphine is a mu-opioid partial agonist. It lacks the danger of
overdose associated with methadone and strong evidence supports its efficacy,
(7, 12) although in a meta-analysis, methadone was found to have a marginal
edge in retaining patients in treatment over buprenorphine.(8) Buprenorphine is
often dispensed as a formulation with naloxone (a mu-opioid antagonist with very
high receptor affinity, but not bio-available when taken via sublingual route), thus
fully discouraging intravenous abuse and limiting diversion. Methadone has a
stronger evidence base as a result of its longer history on the market, but many
providers are now using buprenorphine as a first-line treatment option for opioid
dependence.
Of note, clonidine, a drug which increases regulation of adrenergic tone, is
used to mitigate opioid withdrawal symptoms. Clonidine is not considered a
method of maintaining an individual and is only used during acute withdrawal.
Evidence does not support the use of withdrawal as a method of treatment.(7)
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Pharmacologic Treatment of Alcohol Dependence
There are three medications approved by the FDA for the the treatment of
alcohol dependence: naltrexone,acamprosate, and disulfiram. Naltrexone is a mu
opioid receptor antagonist and there is evidence to show that it is the most
effective treatment modality for alcohol use disorders. It is also used in the
treatment of opioid dependence, but the depot formulation was only approved in
late 2010 in the United States. Acamprosate is used to treat alcohol abuse as a
craving-reduction support, but studies suggest that it is only useful in the most
motivated patients.(7) The exact mechanism of action of acamprosate is unclear,
but is thought to relate to glutamine modulation. Disulfiram blocks an enzyme key
to the metabolism of ethanol metabolites, resulting in severe symptoms if an
individual taking the medication consumes ethanol. Disulfiram, again, has been
found to be effective mostly for individuals who have high levels of motivation to
quit drinking.

Non-pharmacologic Treatment of Substance and Alcohol Use Disorders
There are a number of non-pharmacologic means of treatment available
for both substance and alcohol use disorders. Many of these are geared
generally towards the goal of re-establishing rewards separate from drugs of
abuse. Alcoholics Anonymous and Narcotics Anonymous are run on self-help
and support-group models and are very common in the community and in
correctional settings. The effectiveness of these modalities are difficult to
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determine in a controlled way given the inability to control frequency of meeting
participation due to the anonymous nature of the intervention as well as the
difficulty in controlling the contents of the intervention. Understanding that, some
counseling-based interventions have good evidential support. Individual
counseling and case management services have proven to be effective as
community-based interventions to reduce substance use and recidivism,(13) but
a standardized, well-defined intervention has not been widely validated.
Therapeutic communities (highly structured group housing and therapy) are the
only intervention with solid evidence to support its effectiveness in the
incarcerated population.(14) However, its effects are short-lived in those who
only undergo treatment in the prison milieu and individuals clearly require further
community-based treatment for prolonged treatment success to occur.(15)

Goals of Substance Abuse Treatment
The goals of substance abuse treatment are several-fold. The maintenance of
sobriety is a main goal, with its hopefully accompanying return to more optimal
living circumstances. The idea of reducing harm to users (be it sexual risk,
injection-related risk, etc) and reducing criminal involvement are also important
endpoints of treatment. Opioid agonist treatments have been proven to achieve
these goals well for opoiod abusing individuals. One important benefit of opioid
agonist treatments is that they reduce injection and thus the health risks
associated with it (HCV, HIV transmission, abscesses, etc).(7, 16) Outpatient
treatment with opioid agonists reduces law infractions and incarcerations,
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suggesting fewer substance-use-associated risks taken.(17) Also of note, studies
have shown that the primary cause of death after release from prison is drug
overdose(18, 19) – harm that is abrogated by bridging to appropriate, effective
treatment.

Incarceration
The so-called “War on Drugs,” starting in the 1980s, was a nationwide
attempt to curb substance abuse by increasing penalties on those who use illicit
drugs. The ensuing implementation of numerous laws and judicial standards
resulted in a precipitous growth of the criminal justice population. By 2005, 7.1
million people were under some form of correctional supervision(1), with 1/100
Americans behind bars in either prison or jail.(20) From 1980 to 1999, this
reflects an increase of nearly 240%.(21) Sadly, but not surprisingly, the
incarcerated population skews strongly towards young men, as does substance
abuse and dependence (1 in every 30 men in the age bracket 20-34 years of
age are incarcerated). Among those young men, Black men are
disproportionately represented (1 in every 9 Black men aged 20-34 is in
prison).(20)
It is generally accepted that an increase in drug arrests and tightening of
minimum sentencing requirements nationwide has been the major driving force in
the recent burgeoning of the correctional population in the United States.(22)
Importantly, substance abuse rates in this period have been constant (per
SAMHSA numbers) while substance abuse-related incarcerations have been on
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the steep rise.(23) In 1986, only 9% of state prisoners were incarcerated for drug
law violations.(24) Over the following years, these aggregated national numbers
increased to nearly 25%.(25) This national growth was more pronounced in some
states as some states ramped up the proportion of offenders incarcerated for
drug-related charges tenfold over the period from 1980-1998.(26) The New York
State Department of Criminal Justice reports the number of arrests for drugrelated crimes (led by possession) sharply increasing after the year 1996.(27)
Numbers from California reflect a similar timeline with an arrest and incarceration
profile increasingly laden with drug offenders.(23, 28)
This increase in arrests has concentrated a large number of individuals with
substance use disorders in our nation’s correctional agencies. 2002 self-report
statistics from the Bureau of Justice Statistics indicate that 53% of inmates were
abusing or dependent on substances at the time of their arrest and 68% of
inmates were abusing or dependent on either drugs or alcohol or both.(29) Urine
drug test estimates from the same time period suggest that 67% of male and
68% of female arrestees tested positive for drugs (23% tested positive for more
than one substance).(30) The correctional health care system was woefully
unprepared for this influx, and rigorous, evidence-based treatment has not been
the standard.(31)
Clearly then, the main method of dealing with the issue of substance
abuse is simply to incarcerate those who use drugs. In a 2002 paper, Hammett,
et al report data that indicates a rate of 0.38 arrests per year per drug user in a
large, multi-city United States data set.(32) This high rate of incarceration is
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reflected again in statistics on re-arrest: 70% of individuals in prison with
substance abuse or dependence problems had a prior sentence and 47% of the
same population had 3 or more prior imprisonments.(29) Many of these reincarcerations occur for drug use-related violations of parole terms.(25)
This tendency towards re-incarceration is due to the fact that offenders
with substance use disorders tend to have high rates of relapse to addiction,
overdose after release, and high levels of HIV risk, and crime.(15) Many
releasees return to social circumstances not unlike those they left before
incarceration and face the same challenges and situations that contributed to
their incarceration in the first place. (13, 33) There is strong neurobiological
evidence indicating that many of these situations involve cues that are tightly knit
in the brains of offenders with substance use disorders and all of the behaviors
associated with it. (6, 34) Additionally, relapse is highly likely once the
neurobiological shift to addiction has occurred. (35) In the absence of treatment,
incarcerating individuals with substance use disorders is thus the equivalent of a
revolving door - an expensive one.
Considering the current economic climate, cost to society is an important
consideration in all public policy decisions and is an important piece of the
argument for substance abuse treatment in corrections. In 2008, United States
governments (local, state, and federal) spent roughly $75 billion on
corrections.(36) An example of this high cost of incarceration can be seen in the
case of California: in 2004, each new incarceration cost the state an average of
$30,929.(28) Moreover, 73% of drug-related and 73% of property crime-related
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offenders were found to be dependent on or abusing drugs at the time of their
crime,(29) confirming the role of substance abuse in property crime, a significant
social cost. Treatment that reduces the burden of substance abuse can thus
result in lower criminality as well as lower rates of risky behavior, reducing the
burden of crime on society as well as the burden of disease on individuals and
society alike. Considering these costs as comparable social costs, various costbenefit analyses show methadone(3, 37, 38) to be a cost-effective treatment
measure. Several cost-effectiveness studies have also shown in-prison treatment
that bridges to community-based treatment to be cost-effective, as well.(21, 39)

Substance Abuse Treatment in Corrections: Current State of the Evidence
Taken together, the above evidence points strongly to the need for
treatment of substance and alcohol use disorders in correctional settings for,
“prison may provide the only opportunity that a marginalized population has to
engage with treatment services.”(40) At this nexus of social problem and public
policy lies a burden of substance abuse on individuals suffering from such
disorders, the burden of crime and lost productivity on society, and a burden on
government finances wrought by high usage of incarceration alone as a policy for
dealing with substance abuse. Evidence indicates that there is a clear role for
including substance abuse treatment in corrections. This inclusion can be likened
to “case finding” in infectious disease outbreaks and “targeted intervention” in
many public health endeavors.
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Prisons and jails have been a difficult place to encourage treatment of
drug and alcohol use because of an emphasis on security and punishment over
rehabilitation and support.(41) Historically, this has been the case for all of health
care in prisons and jails. International agreements on prisoners’ rights have
attempted to counteract this by arguing that, from a human rights perspective,
the punishment of confinement is punishment enough; restricting health care
access and inflicting subhuman treatment on prisoners is a violation of their
inherent rights.(42)
Substance abuse treatment in the correctional context has been studied
and there is an increasingly strong body of evidence in the field. There are
several secondary questions that arise around this topic: can someone be forced
to change? Can prisoners be successfully transitioned from in-prison treatment to
out-of-prison treatment? The issue of whether coerced or incentivized treatment
works is a question that has been explored at length. While having treatment
program clients who are ready and willing to change their substance habits
appears to result in more optimal outcomes(43, 44), coercing engagement with
treatment has been shown to be an effective means for reducing substance use
behaviors.(45) This evidence contradicts the conventional wisdom commonly
held by those in the substance abuse treatment field that individuals who are
forced into treatment will resist it and thus render treatment worthless, or that
they will disrupt the treatment milieu and destroy its effectiveness for other
clients. This data provides a substantial foundation for the idea of placement of
treatment into such a strongly coercive environment as a prison or jail.
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Understanding that treatment in coercive environments can work and that
the evidence in community-based treatment shows definitively that medicationassisted therapy (MAT) is the treatment of choice, several well-designed studies
have shown the effectiveness of in-prison methadone maintenance therapy in
reducing re-arrest, post-release mortality, increasing adherence to communitybased treatment after release, and reduction in post-release drug use. Generally,
studies support the use of opioid agonist therapy in correctional populations and
find that, with a sufficiently high dose of medication, retention in treatment is quite
good.(46)
A 1992 study performed at Riker’s Island in New York, examined
enrollment and retention in MMT after a jail term that included either induction
into or continuation of MMT after booking. At 6-month follow-up, 27% of those
who received MMT in jail were retained in community MMT treatment, while only
7% of jail-detoxed controls were retained. Significant positive effects on postrelease criminality and substance use were associated with in-jail MMT.(47)
In 2005, Kinlock, et al published a study in a cohort of prisoners that
replicated these results for a prison population. They showed clearly that prerelease maintenance therapy initiation was associated with entry into treatment in
the community.(15) Kinlock’s group then performed a prospective study of in-jail
MMT in Baltimore, MD and subsequently performed 1-month and 1-year followups with follow-up supporting a combination of counseling/case management
and opioid replacement therapy. (48, 49)
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Dolan, et al performed a more rigorous follow-up four years after their inprison MMT trial. Most significantly, releasees who were retained in MMT
treatment for longer than 8 months had a lower risk of re-incarceration by an
adjusted hazard ratio of 0.3 (0.2 – 0.5, p < 0.001). They also found that
individuals who stayed in treatment longer were less likely to drop out of
treatment as time went on. This may indicate bias in the population retained in
treatment, or this may indicate a cumulative effect of treatment. They found at
follow-up that all deaths (17 deaths out of 382 total participants) occurred in the
out-of-treatment part of the cohort, suggesting a protective effect of MMT.(50)
A very recent study examined the harm reduction effects of opioid
substitution agonist therapy in prisons. This research suggests that OST in
prisons reduces these risky behaviors while in prison, as it has been shown to
outside of prison.(16)
With the effects of specific MAT interventions in mind, there’s also
evidence that just being observed by a program positively affects drug-related
criminal outcomes. While under the supervision of a day reporting center,
arrestees sentenced to complete a diversion program had fewer arrests for drugs
while under supervision than those who were not assigned to complete the
supervisory program. The effect was seen regardless of program content. (51)

Politics and Substance Abuse Treatment in the Correctional System
Despite the large amount of evidence to support initiation of rigorous,
extensive substance abuse treatment programming in the correctional setting,
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attempts by state and local governments to take a different tack on substance
abuse have thus far been too small and too short-lived. Several notable policy
interventions have been undertaken in states like Arizona (Proposition 200), New
York (Riker’s Island’s KEEP program), and California (Proposition 36). In the
interest of highlighting the central role of politics in the question of how to deal
with substance abuse and dependence in the correctional system, a brief
discussion of California’s Proposition 36 will follow.
California’s Proposition 36 (The Substance Abuse and Crime Prevention
Act) was an alternative to incarceration for first- and second-time offenders that
sent offenders to various community-based treatment programs and amended
parole-violation laws to mandate community treatment, not in-prison, sentencing.
Initially, the program was hobbled by California’s budget crisis. Although the
legislation included provisions that promised to prevent drawing funds away from
other state-funded substance abuse treatment efforts, Governor Gray Davis did
exactly that in the face of worsening budget crisis.(52) This shifting of programs
was made especially visible in a 2007 study by Hser, et al noting clear
displacement of previously “voluntary” clients out of the substance abuse care
system by new clients mandated to treatment.(53) Of note, Governor Davis
opposed the Proposition and it was widely speculated that this re-shuffling of the
state substance abuse treatment budget was a thinly-veiled attack on the
Proposition – without the other substance abuse treatment programming funded
by the state, offenders sentenced under Proposition 36 faced limited numbers of
program slots and prior offenders who were in treatment were bumped from
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treatment. Adding to this fiscal opposition from the governor’s office was political
opposition from California’s drug court judges, district judges correctional officers’
unions, and District Attorneys.(54)
Thus, the program faced difficulty in enforcing engagement with treatment
– a full 25% of those sentenced to mandatory treatment failed to enroll in
treatment and not 50% of those who enrolled completed treatment.(55, 56) This
failure to enroll in and complete treatment is likely a result of an attempt at
increasing the number of individuals receiving treatment while simultaneously
maintaining, or even decreasing, available treatment slots – the result of an
unsympathetic governor and budget.
Even in the face of political interference, a significant economic impact
was realized under Proposition 36: for every dollar spent, $2.50 in value was
returned to the taxpayers. This value increased to $4 in value for every $1 spent
when cost-benefit analysis was limited to those who completed treatment.(56)
Years after its implementation, the courts extended funding on an annual basis
for several years due to the significant benefits that had been realized.
The example of California’s Proposition 36 thus serves as an example of
the influential role of government and politics on substance abuse treatment
programming and its interface with the criminal justice system and the politically
popular “War on Drugs.” The role of an evaluation in this field thus must take into
account the possibility that politics may be playing a role in treatment structures
and must evaluate that role, if possible. Socially impactful programming should
be large-scale and comprehensive and thus must rely on large budgets –
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frequently state budgets. They must also be well integrated within a correctional
system – a state agency. Thus, the political lessons learned from a case like CA
Prop 36 are essential when working in or evaluating the field of substance abuse
for offenders.
When the United States is considered alongside other developed nations,
the dearth of evidence-based substance abuse treatment and harm reduction in
our correctional system becomes comparatively more obvious. Internationally,
MMT has been made available in many prison systems, but the United States
continues to provide little to no access to this evidence-based therapy.(49)
Canadian studies have shown efficacy of institutional MMT programming in
reducing criminality and drug use.(57) After this study and a lawsuit by a
prisoner, Canada expanded its in-prison methadone maintenance access in
2002.(58) Australia made MMT available to inmates in the 1990s and the positive
effects of treatment implementation included a reduction in in-prison injection of
drugs(59), and less drug use after release. Germany made clean syringes
available to inmates in several prisons in 2000 and saw a reduction of in-prison
needle sharing as a result, but the program was short-lived, caving under political
pressure.(60)
All of this evidence and expert opinion should suggest that drug abuse
treatment would be more widely implemented in criminal justice settings.
However, evidence-based practice for substance abuse treatment is only partially
implemented.(61) A recent survey of methadone and buprenorphine provision in
U.S. prisons showed widespread reports that methadone was made available to
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inmates in 55% of state prison agencies. More than half of these only provided
methadone to pregnant women or as pain medication, however, and few offer
MMT. Even fewer offer buprenorphine (14%) in any capacity. Only 45% of
agencies confirmed referring any releasees to community-based MMT
treatment.(62) There are obstacles to advancing MAT usage in the correctional
setting, but were not defined by this study.
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Statement of Purpose and Hypothesis

The purpose of this study is to explore the factors associated with the
implementation of various kinds of substance abuse treatment, with a special
focus on MAT, to fill an important gap in knowledge in an effort to direct efforts at
implementing evidence-based practice in correctional substance abuse
treatment.
We hypothesize that funding will be ranked by respondents as a major
obstacle to substance abuse programming, past and future. We hypothesize that
funding will also be the most important factor contributing to willingness to
consider more robust substance abuse treatment programming. We further
hypothesize that in a multivariate model, factors including geographic location,
budget, knowledge and attitudes about MAT, facility size, overcrowding, and
institutional pressures will be noted as significant covariates of MAT-based
treatment implementation.
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Methods

Population and Data Collection
The survey sample was drawn from a previously identified national sample
of prisons, jails, and community corrections units identified through a
randomization protocol designed during a prior large-scale national survey of
correctional facilities (the National Criminal Justice Treatment Practices survey
[NCJTP], a NIDA-funded project). The NCJTP survey effectively identified
prisons that implement medication-assisted therapy (MAT) for substance abuse
treatment (SAT) programming and others that do not.(25) The sample was taken
from areas of the country with higher drug abuse rates and larger populations,
both indicators of likely high rates of incarceration for drug abuse-related crimes.
Their randomization procedure was undertaken with the aim of generating a
similar broad, national sample, but one that was focused more on drug abuse
issues than a purely random sample might be. Using a random number
generator, each facility was assigned a 5- or 6-digit code, with a database of
each facility’s code kept on a secure encrypted server. For the purposes of
follow-up, these codes were attached to facility names. Once data collection
began, the responses were dissociated from their facility names.
Of note, a single case was discovered from the original randomization that
constituted a duplication because the county jail and its associated sheriff’s office
were both included in the sample inadvertently. One of the cases was removed
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and the response was only weighted once because only one correctional unit
was represented.
Survey responses were collected from August 2011 until April 2012. The
sampling strategy is diagrammed in Figures 1 and 2. We relied on each unit to
direct the survey to the appropriate respondent within their organization, be they
a health services administrator, a warden, or other administrator who directs
substance abuse treatment programming for that unit. The survey packet was
mailed to each unit in the random sample. Follow-up was conducted using
telephone and e-mail contact along with redistribution of survey materials when
required.

Instrument Design Procedure
The survey instrument is available in Appendix A. The mail-based survey
instrument used in this study was designed in a multi-phase fashion.1 First, an
extensive search of the related literature was done to ascertain the existence of
other surveys in the field that focus particularly on the opinions of administrators
within the correctional system. Though the literature on substance abuse in
correctional health care is relatively thin, several examples of previously
executed surveys were found. (25, 63-65) To gain an understanding of the
current standards of practice, published standards were studied.(66, 67) These
were studied along with the defining texts on the subject(68-70) and a draft
instrument was designed, drawing questions and frameworks from existing work.
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  

1	
  Note:	
  The student author was lead instrument designer, was trained to lead and ran focus groups,
managed contacts with collaborators, submitted protocols and forms to the Yale School of Medicine HIC,
managed survey response and follow-up, and performed data entry and analysis.	
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The instrument was designed to focus on areas of organizational structure
identified in previous work. (25, 61, 71) Particularly, funding, overcrowding, and
attitudes scales regarding past, present, and future barriers were included. Other
data on staffing change (as a measure of organizational instability) and
methadone knowledge and attitudes (adapted from McMillan, et al(72)).
Questions regarding particular numbers (i.e. populations, budgets) were
standardized by requesting that facilities report their FY 2009-10 numbers for
those categories.
In accordance with the recommendations of the survey design texts
studied, the draft was presented to a focus group of administrators as well as
treatment staff at the Connecticut Department of Correction. This group was
made up of individuals who hold positions that mirror those of our target
respondent population. The feedback from this session was integrated into the
second draft of the instrument, which was subsequently distributed to a group of
experts in the field for a second round of feedback. Again, comments and
criticism were integrated into a third draft of the instrument, which was then
presented to the Human Investigation Committee at the Yale School of Medicine
where it was approved, along with accompanying documentation (anonymousstyle informed consent form and cover letter).
While designing the instrument, we also considered work in the field of
survey response rate and organizational characteristics that might affect it.
Historically, surveys of organizations have poorer response rates than surveys of
individuals (rates between 30 and 65% response have been reported for
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organizations versus 70 to 75% in individual surveys) and this may be due to the
hierarchical, bureaucratic nature of organizations and the ability of individuals
within them to pass a task such as a survey off as “not my job.”(73) In order to
combat this tendency and increase our study’s relevance to our target group of
respondents, we explored allying ourselves with the American Correctional
Association (the professional association for wardens and commissioners of jails
and prisons). In the end, however, we were unable to facilitate this partnership
and instead obtained a letter of endorsement from Dr. Faye Taxman, Principal
Investigator of a number of large criminal justice surveys, with whom many of the
recipients would be familiar.
Other barriers to response within organizations include survey length as
well as restrictions on respondents’ time that make them unable to respond.(74)
In order to combat the former, with each revision of our drafts, we shortened the
instrument as much as possible. The latter barrier has been approached by
ensuring that individuals have organizational support to complete the survey
within normal business hours, with pay.(25) We were unable to provide this
incentive, however.Without greater grant support, we were unable to ensure such
financial or time support, however.

Data Reporting and Measures Employed
All information was collected by self-report by administrators designated
by each facility. Data are reported by region and by facility type, but reporting
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further detail on facility size and location of respondents by state was avoided to
maintain sufficient anonymity of response.
For purposes of data analysis, average daily population was parsed into
quartiles (0-414, 415-1260, 1261-1873, 1874 and above). A measure of
overcrowding was created by calculating the difference between average daily
census and stated maximum capacity. The reported budget for FY 2008-09 was
parsed into quartiles, as well (0-3036500; 3036501-46200000; 46200000447000000; 447000001-top). A measure of the comparative weight of substance
abuse programming within the budget was calculated by taking the ratio of
monies earmarked specifically for substance abuse treatment programming as a
percent of the total organizational budget. The inter-quartile split was (0-0.0000;
0.0000-0.4314; 0.4315-1.7638; 1.7639-top)
When reporting current program implementation, respondents were asked
whether programs or treatments were currently available and not whether
individuals were actually receiving programming. It is assumed that some
programs may be highly utilized and that some may be underutilized. Program
flux was measured as any reported increase or decrease in slots or program
opening or closure in the two years prior to survey completion. Factors
contributing to increase or decrease were scored on a 0-2 scale in which 0=No
contributor to change, 1=Minor contributor to change, and 2=Major contributor to
change. Mean scores were assigned. Only those units indicating that changes in
programming had occurred were asked to rank factors contributing to program
change. Openness to future program implementation was asked in light of the
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respondent imagining that all barriers to opening a kind of treatment
programming were removed.
Knowledge and attitudes about methadone was measured using scales
devised by McMillan and Lapham, 2004.(63). Knowledge scales about
buprenorphine and naltrexone were not available in the literature and it was
beyond the scope of this project to design and test new scales. The knowledge
scale is a 14-point scale and the attitudes scale is a 13-point scale (available in
Appendix A). For the purpose of logistic regressionstatistical analysis, cutoffs
were established at the points of central tendency. Both scores were roughly
normally distributed. Knowledge scores centered around a mean of 9.2 and a
median of 9.0, so a score of 9 was used as a cutoff. Attitude scores were
centered around a mean of 8.5 and a median of 8 and 8 was used as a cutoff
score.
Regional breakdown of the original sample was done using a map
generated for prior Department of Justice studies of the criminal justice system.

Data Analysis
All data was double-entered by hand by the author and double-checked by
the author. Of note, some data were submitted by state-level agencies and not
local units because of variations between states in the way that decision making
regarding substance abuse treatment is made. In several states (CO, DE, FL, MI,
MN, MO, OK, VA, WA), substance abuse treatment programming is administered
solely at the state level and units were instructed that it would be inappropriate
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for them to respond individually. In these cases, background data for several
measures (inmate population, maximum capacity, funding) were given for the
entire state agency. These numbers were roughly adjusted by dividing the
indicator by the total number of units administered by the agency (whether or not
they were included in our random sample; this data obtained through each official
state DOC website) to obtain a mean indicator for that state. Each case for those
states (total 41/124 responses) is thus represented by these adjusted means for
the indicators mentioned above.
Several indicators measured attitudes or perceptions regarding
contributors to recent program closure and expansion or perceptions regarding
potential barriers to future treatment programming efforts. These indicators were
measured by a Likert-scale response attributing the estimated magnitude of
contribution of the given indicator to the given scenario (e.g. what was the
possible contribution of new state funding on recently expanded programming).
The Likert scale responses were assigned point values and a mean score was
calculated for each. Chi-square analyses were also performed to determine
whether the empiric differences in score found within contributors were
measurably valid.
Primary outcomes of interest were the implementation of MAT (measured
as facilities reporting implementation of any MAT - MTD, BPN, or NTX); whether
a respondent indicated that they had a positive attitude towards implementing
MAT (measured as a response of “Already Implemented,” “Would Implement,” or
“Would Consider Implementing” when asked if what their attitude is towards MAT
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for maintenance, alcohol abuse, or combined with counseling). These two
outcomes were summed to a final binary outcome of “Would consider or already
implements MAT.”
All statistical analyses were performed using SPSS v.19.0 (IBM, 2010).
Chi-square and ANOVA were used to analyze differences between reported
means. Univariate and multivariate logistic regression were used to determine
the influence of various factors on the noted variables of interest.

	
  

29	
  

	
  

	
  

	
  
Results

The final sample was ultimately representative of a national survey of
criminal justice settings. Of the 226 sites sent the original survey, the overall
response rate was 54.9%, with the final sample comprised of 124 diverse
facilities. Though overall, each region was represented similarly (p = 0.159; see
Table 1), there was a trend towards increased representation of facilities in the
Midwest and Southeast. The response rate, however, was significantly lower in
facilities in the Southwest and Northeast (p<0.001; see Figure 1). Regarding
facility type, the final sample was similarly distributed with 63% of jails, 53% of
prisons, and 50.0% of community correctional settings responded to the survey.
As a portion of the total sample, prisons make up a significant majority (p <=
0.0010; Table 1), but there was no difference in response rates between facility
types (p = 0.332; see Figure 2).
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Figure 1: Sampling Flow Diagram, by Region of U.S.
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Figure 2: Sampling Flow Diagram, by Facility Type
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Table 1: Characteristics of Survey Respondents
Total (n)
Total response rate
Sample Composition (n=124)

Chi-square (p)

54.9% (124)

Jails
Prisons
Community Corrections

29.0% (36)
54.8% (68)
16.1% (20)

<0.001

Northeast
Southeast
Midwest
Northwest
Southwest

15.4% (19)
26.6% (33)
24.4% (30)
18.7% (23)
15.4% (19)

0.156

1817 (SD=3207)
1602 (SD=1957)
1660 (SD=1225)
2592 (SD=7342)

<0.05†

Mean Daily Population (All sites)
Jail (n=36)
Prison (n=68)
Community Corrections (n=20)
Percent of responding facilities
operating over stated capacity (n=114)
Median percent of 2009-10 budget
designated for SAT (n=94)

19.8% (23)
0.41%

Any recent increase in budget
designated for SAT (n=107)

22.4% (24)

Any recent decrease in budget
designated for SAT (n=107)

33.6% (36)

No change in budget designated for
SAT (n=104)
Currently SAT services (n=124)
Offers any SAT
Screening
Referral
MAT-Based Programming
Methadone
Buprenorphine
Naltrexone
Counseling-Based Programming
12-step program (AA/NA)
Individual counseling
Group counseling

43.3% (45)
82.1% (101)
79.8% (99)
80.6% (100)
15.3% (19)
2.4% (3)
0.8% (1)
87.9% (109)
69.3% (86)
73.4% (91)

Legend:
SAT: Substance Abuse Treatment
MAT: Medication-Assisted Therapy
AA: Alcoholics Anonymous
NA: Narcotics Anonymous
†=ANOVA used to detect difference between mean population sizes
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The average daily population census reported by facility type varied widely
(Table 1). Of the 36 jails responding, the mean reported daily population was
1,602 (range: 2 to 9,000; SD= 1,957). Variation in the prison population was
similar with a mean of 1,660 (range: 30 to 5,500; SD=1,225). Community
corrections units reported a mean population of 2,592 (range: 37 to 32,000;
SD=7,342). Nearly 20% of facilities reported operating over their stated capacity.
Budgets ranged widely. The percent of the budget specifically earmarked
for substance abuse treatment, however, was almost uniformly low, with a
median of under 1% (0.41%) of the total operating budget set aside for this
purpose. A majority described recent changes to their substance abuse
treatment (SAT)-specific budget with 33.6% reporting a recent decrease and
22.4% reporting a recent increase.

Current Substance Abuse Treatment Practices
A majority (82.1%) of all facilities reported offering some kind of substance
abuse treatment (SAT) programming for inmates. In accordance with the
standards set forth by the National Commission on Correctional Health Care,
baseline care for inmates who need substance abuse treatment, (66, 67) a
majority of facilities have systems for screening for and referral to SAT (see
Table 1).
More facilities offered counseling-based treatment than MAT. Nearly all
offer 12-step programming, either Alcoholics Anonymous (AA) or Narcotics
Anonymous (NA) (n=109; 87.9%), group counseling (n=91; 73.4%), or individual
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counseling (n=86; 69.3%) while a minority (n=20; 16.1%) of respondent facilities
offers any MAT. Nineteen (15.3%) offer methadone (MTD), even fewer (n=3;
2.4%) offer buprenorphine (BPN), and 1 offers naltrexone (NTX). The number of
individuals receiving MTD in those facilities providing it varies widely (mean = 85,
SD = 152). Of those who stated they do provide MTD, 82.4% are generally
satisfied with it. Of note, only 8 of the respondents who indicated that they do not
provide methadone in their unit noted that they do not have individuals who
would benefit from MTD treatment; community corrections units were more likely
to indicate this (p<0.001) but there was no statistical difference between regions
(p=0.183).
There is a significant difference in which regions offer any substance
abuse treatment services (p = 0.065; see Table 2), favoring the Northwest,
Northeast, and Midwest. MAT, similarly, is disproportionately offered in these
regions (p < 0.05; see Figure 3). There is a significant difference in which
facilities offer any substance abuse treatment (p < 0.01; see Table 3), favoring
prisons. Jails, however, disproportionately offer MAT (p < 0.001; see Figure 4).
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Table 2: Availability of and Attitudes About MAT for Substance Abuse Treatment by Geographic Region

All

Northeast
(19)

Southeast
(33)

Midwest
(30)

Northwest
(23)

Southwest
(19)

Chi-Square

Any SA Treatment
available (n=124)

81.5% (101) 94.4% (17)

90.9% (30)

76.7% (23)

82.6% (19)

63.2% (12)

0.065

Any MAT currently
available (n=124)

16.1% (20)

26.3% (5)

3.0% (1)

13.3% (4)

34.8% (8)

10.5% (2)

<0.05*

MMT

15.7% (19)

27.8% (5)

3.0% (1)

13.3% (4)

34.8% (8)

5.3% (1)

<0.01†

BPN

2.3% (3)

0 (0)

0 (0)

3.3% (1)

4.5% (1)

5.3% (1)

0.678

NTX

0.8% (1)

0 (0)

0 (0)

3.3% (1)

0 (0)

0 (0)

0.559

55.7% (64)

58.8% (10)

16.7% (5)

80.0% (24)

70.0% (14)

61.1% (11)

<0.001‡

If barriers were
removed, would add
new SA treatment
programming (n=116) 93.1% (108) 88.9% (16)

100% (28)

89.7% (26)

95.7% (22)

88.9% (16)

0.428

Implements or would
consider
implementing MAT
(n=115)

*=Significant at p<0.05
†=Significant at p<0.01
‡=Significant at p<0.001
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Table 3: Availability of and Attitudes About MAT for Substance Abuse Treatment by Facility Type

All

Jail (36)

Prison (68)

Community
Corrections
(20)

Chi-square

Any SA treatment
available (n=124)

81.5% (101)

66.7% (24)

92.5% (62)

75% (15)

<0.01†

Any MAT currently
available (n=124)

16.1% (20)

38.9% (14)

7.5% (5)

5% (1)

<0.001‡

MMT

15.4% (19)

36.1% (13)

7.5% (5)

5.0% (1)

<0.001‡

BPN

2.3% (3)

5.6% (2)

1.6% (1)

0 (0)

0.346

NTX

0.8% (1)

0 (0)

1.5% (1)

0 (0)

0.658

Implements or would
consider implementing
MAT (n=115)

55.7% (64)

64.5% (20)

51.6% (33)

55.0% (11)

0.491

If barriers were
removed, would add
new SA treatment
programming (n=116)

93.1% (108)

87.9% (29)

96.8% (61)

90.0% (18)

0.216

*=Significant at p<0.05
†=Significant at p<0.01
‡=Significant at p<0.001
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Figure 4: Current Availability of Any MAT (methadone, buprenorphine, or
naltrexone)
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Recent Changes in Programming
About 70% of the sample indicated that some change in SA programming
had occurred in the last 2 years with 53 respondents indicating some increase in
programming and 35 indicating some decrease in SA programming. The great
majority of respondents in the Northwest (77.3%) indicated recent program
decreases (Figure 5) with almost 50% of respondents in the Southwest similarly
reporting decreases, and a minority of respondents in the Midwest, Northeast,
and Southeast reporting decreases in programming (p<0.001). The majority of
respondents in the Southeast (71.9%) and Midwest (55.5%) reported some
recent increase in SA programming, with roughly a third of respondents from the
Southwest and Northeast and a minority of respondents from the Northwest
reporting recent increases (p<0.001; see Figure 6).
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Figure 5:
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Figure 6:
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When examined by facility type, there was no statistical difference across
all three types (p=0.305), nor was there a significant difference between groups,
among those reporting recent decreases in SA programming. An empirically
greater proportion of community corrections units reported decreases than jails
or prisons (Figure 7). Prisons were more likely than jails or community
corrections units to report programming increases (p<0.001; see Figure 8).

Figure 7: Programs Reporting Recent Decrease in Programming, by Facility
Type
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Percent reporting recent increase in SA programming

Figure 8: Programs Reporting Recent Increase in SA Programming, by Facility
Type
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Respondents who reported programming decreases were asked to rank
possible contributing factors to program contraction (Figure 9) on a scale of no,
minor, or major contributor to decrease. Funding cuts were the only factor with an
aggregate score above 1 (where 1 = “minor contributor to decrease”). Other
factors such as “leadership dissatisfaction with programming” and “no proof that
MAT works” were not even considered to be minor contributors to decrease.

	
  

44	
  

	
  

Figure 9: Factors Contributing to Recent SA Program Contraction (n=35)
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Respondents who reported program increases were similarly asked to
rank possible contributors to increase (Figure 10) using a similar scale. “Excess
need for treatment services” tallied the highest aggregate rank, but “reduction of
recidivism,” “new support from leadership,” “new federal funding,” and “new state
funding” were all ranked above a score of 1 (minor contributor to increase).

Figure 10: Factors Contributing to Recent SA Program Expansion (n=53)
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Future Treatment Consideration
When asked broadly whether they would consider increasing
implementation of any SA treatment programming should all barriers to doing so
be removed, 93.1% of respondents indicated that they would. There was no
difference between geographic groups or facility types (Tables 2 and 3, pp 3536).
When asked about particular programs (Figure 11), roughly 60% of
respondents indicated that they would not consider implementing MAT
programming in the absence of counseling (either for opioid or alcohol abuse)
and 45% would not consider offering MAT with counseling. In contrast, the great
majority of respondents already had counseling-based programming in place
(92.4% reported implementation of 12-step programs, 74.1% reported individual
counseling and 77.8% group counseling) and few reported unwillingness to
implement future counseling-based SA programs.
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Figure 11: Current and Future Implementation of SA Programming
Counseling Programs
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When the responses to program-specific questions about future
implementation were divided by region, the only region in which fewer than half
of respondents were opposed to implementing MAT alone for opioid dependence
was the Northwest (35% opposed; see Figure 12) with the Southeast most
opposed to this option (83.3%). Most regions were less opposed to MAT with
counseling (23.3%-41.9%; see Figure 13), but the Southeast registered higher
rates of opposition (83.3%).
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“Lack of funding” topped the list of perceived barriers to any possible future SA
treatment programming (Figure 14) as the only barrier with a mean score near 3
(“Significant barrier”) and a median score of 3. Other barriers ranked between 2
(“Moderate barrier”) and 1 (“Minor barrier”) were “Lack of physical space” (1.62),
“Lack of qualified staff” (1.49), “Organizational capacity” (1.41), and “Public
attitudes” (1.03).

Figure 14: Perceived Barriers to Potential Future SA Treatment Programming
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Attitudes Towards MAT
Results from regional and facility-type stratification of the combination
variable of interest, “Would you consider or do you currently implement MAT?”
followed similar regional trends. Respondents from the Southeast were
significantly more likely than those from other regions to indicate that they would
not be interested in offering or considering MAT programming (p<0.001; Figure
15). There is no significant difference between facility type in whether
respondents indicate that their units currently offer, or would consider offering,
MAT programming (p = 0.491; see Figure 16).
Of note, two important variables were found to be collinear with attitude
scale scores. Facility type was also found to be collinear with attitudes (B=0.41;
95% CI: 0.21, 0.82; p<0.001). When parsed by facility type, having reported from
a jail had a significant relationship with attitudes, with a higher score resulting if
the respondent were reporting from a jail (B=3.17; 95% CI: 1.23, 8.18). Being a
respondent from a prison or a community corrections unit was not significantly
associated with attitudes scores. Knowledge scores and attitudes scores were
also found to be collinear with greater knowledge predicting more positive
attitudes (B=5.03; 95% CI: 3.35, 6.81; p<0.001).
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Figure 16: Positive Views on MAT – Percent who implements or would consider
MAT, by Facility Type (n=123)
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Role of Knowledge
When asked about their awareness of studies to support various SAT
programs in their population, respondents indicated that counseling-based
programming was more supported by the literature than MAT-based
programming. They were also more likely to indicate that they were unaware of
the studies of MAT-based programming (Figure 17). Using bivariate correlations,
it was noted that those who responded that they were unsure about studies for
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one type of MAT usually responded that they were unaware of the evidence for
other kinds of MAT (Table 4). Upon further inspection, lack of knowledge about
studies negatively influenced respondents’ willingness to consider MAT (Table
5).

Figure 17: Awareness of Relevant Studies in Selected Areas of SA Treatment
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Table 4: Correlations Between “Unsure” Reponses on Questions About Pertinent
Studies on SA Treatment Programming

Unsure of Studies
on:

MAT for
treatment of
withdrawal

MAT for treatment
of withdrawal

1

MAT for
maintenance
MAT for alcohol
abuse
MAT plus
counseling

0.957‡
n=92
0.916‡
n=92
0.822‡
n=92

MAT for
maintenance

MAT for
alcohol
abuse

MAT plus
counseling

1
0.892‡
n=93
0.805‡
n=93

1
0.829‡
n=93

1

*=Significant at p<0.05
†=Significant at p<0.01
‡=Significant at p<0.001

Table 5: Bivariate Correlations Between Respondents Who Are “Unsure of
Studies in My Population” and “Would Consider Implementation”

Unsure of
studies on
MAT to treat
withdrawal

Unsure of
studies on
MAT for
opioid
dependence

Unsure of
studies on
MAT for
alcohol
dependence

Unsure of
studies on
MAT and
counseling

-0.383‡
n=91
-0.219*
n=91
-0.178
n=91
-0.217*
n=91

-0.383‡
n=92
-0.257 †
n=92
-0.183
n=92
-0.232 *
n=92

-0.402‡
n=92
-0.227*
n=92
-0.159
n=92
-0.212*
n=91

-0.459‡
n=92
-0.303†
n=92
-0.212*
n=92
-0.293†
n=92

Would Consider:
MAT to treat
withdrawal
MAT for opioid
maintenance
MAT for alcohol
dependence
MAT and
Counseling
*=Significant at p<0.05
†=Significant at p<0.01
‡=Significant at p<0.001
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Regression Analysis of Factors Contributing to Implementation of MAT
Univariate logistic regression was performed to measure the fit of a
number of covariates included in the original model (region, facility type, unit
census, budget, overcrowding, organizational flux, knowledge, and attitudes; see
Table 6). Two factors were significantly predictive of any MAT implementation
(MTD, BPN, or NTX): Facility type (B=0.16; 95% CI: 0.06, 0.44) with jails more
likely to implement MAT and; Attitudes score (B=10.21; 95% CI: 2.14, 48.72), for
which a higher attitudes score was predictive of MAT implementation. An
additional factor was nearly significantly associated (p=0.06): Percent of budget
dedicated to SA treatment (B=0.63; 95% CI: 0.39, 1.04). In multivariate
regression including these covariates as well as knowledge score (Table 6b),
only attitudes score remained significantly predictive of MAT implementation
(B=6.12; 95% CI: 1.05, 35.73)

	
  

58	
  

	
  
Table 6: Covariates Contributing to Implementation or Positive Views on
Implementing MAT Programming
Covariate

Region (n=115)
Facility type (n=115)
Average daily census
(n=111)
Overcrowded (n=107)
Total budget size (n=97)
Percent of budget
earmarked for SA treatment
(n=89)
Any recent increase in SA
treatment budget
Any recent decrease in SA
treatment budget
Any increase in
administrative staff (n=92)
Any decrease in
administrative staff (n=92)
Any increase in SA
treatment staff (n=92)
Any decrease in SA
treatment staff (n=92)
Any increase in correctional
officer staff (n=93)
Any decrease in
correctional officer staff
(n=93)
Knowledge score (n=86)	
  
Attitudes score (n=86)	
  
Knowledge score (cutoffs)
(n=86)	
  
Attitudes score
(cutoffs)(n=86)	
  
	
  

Implements MAT
β (95% CI)
0.50
(0.72,1.69)
0.16
(0.06,0.44)
1.16
(0.74,1.81)
1.21
(0.36,4.10)
1.08
(0.69,1.69)
0.63
(0.39,1.04)
0.66
(0.17,2.53)
0.10
(0.01,0.76)
0.00
0.39
(0.10,1.49)
0.00
0.28
(0.04,2.33)
2.03
(0.36,11.44)
0.83
(0.29,2.40)
1.43
(1.07,1.9)
1.79
(1.26,2.53)
3.25
(0.85,12.43)
10.21
(2.14,48.72)

Implements or willing to
consider implementing
MAT
β (95% CI)
1.41
(1.04,1.90)*
0.79
(0.45,1.39)
-0.93
(0.66,1.30)
0.97
(0.38,2.49)
0.64
(0.44,0.92)*
1.238
(0.86,1.78)
5.71
(1.78,18.33)
0.23
(0.10,0.56)
0.97
(0.08,11.1)
1.18
(0.47,2.95)
WEIRD RESULT
(8.74000000; 0.00,no
upper limit
2.07
(0.77,5.56)
3.21
(0.37,27.95)
0.60
(0.25,1.42)
1.18
(0.98,1.42)
1.27
(1.05,1.54)* (p=0.015)
0.86
(0.34,2.19)
3.08
(1.17,8.11)*
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Table 6b: Multivariate Analysis
Covariate
REF

Implements MAT
β (95% CI)
1.00

Region
Facility Type

0.36
(0.10,1.31)
NS
1.01
(0.50,2.02)
NS

Budget size
Percent of budget
earmarked for SA
treatment
Recent increase in SA
treatment budget
Recent decrease in SA
treatment budget

0.61
(0.25,1.47)
NS
4.24
(0.30,59.30)
NS
0.76
(0.04,14.46)
NS

Knowledge score
Attitudes score

Implements or willing to
consider implementing MAT
β (95% CI)
1.00
1.18
(0.73,1.91)
NS

8.34
(1.36,51.03)
p<0.05

5.30
(1.27,22.06)
p<0.05

0.50
(0.10,2.59)
NS
5.97
(1.48,24.06)
p<0.05

Regression Analysis of Factors Contributing to Implementation or Willingness to
Implement MAT Treatment Programming
The same group of covariates was also tested for fit with MAT
implementation with the addition of willingness to consider MAT implementation
(region, facility type, unit census, budget, overcrowding, organizational flux,
knowledge, and attitudes). Three factors were significant on univariate
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regression: region (B=1.41; 95% CI: 1.04, 1.90); total budget size (B=0.64; 95%
CI: 0.44, 0.92); and attitudes score (B=1.27; 95% CI: 1.05, 1.54).
Five factors were placed into the final multivariate model: region, facility
type, budget size, knowledge score, and attitudes score. On multivariate logistic
regression, only the attitudes score was significantly predictive of likely
implementation or willingness to implement MAT treatment programming
(B=4.93; 95% CI: 1.25, 19.52).
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Discussion

This study is among the first to examine in detail the availability of MAT in
the United States correctional setting. Other recent studies have examined the
availability of counseling-based treatment programming(25, 61), one has
examined the availability of methadone and buprenorphine in state prisons(62)
but not the related factors, and one has examined some factors contributing to
MAT-based programming.(75) Our findings that substance abuse-specific
funding is an important factor in whether MAT-based programming is
implemented is unique. Our finding that administrator knowledge and attitudes
play an important role in whether MAT is available in their system and in whether
they would consider MAT coincide with Friedmann’s work.(61, 75) The apparent
interplay of positive attitudes towards methadone with substance-abuse-specific
funding in administrators’ willingness to consider MAT-based therapy in their
units is also a unique and compelling finding.

Lack of MAT Availability
Our study reports the availability of programming, not the utilization of
programs. Other studies have focused more on actual utilization and this work
indicates that relatively few inmates are receiving treatment of any kind (22, 25),
and even if significant advances were made in the intervening 5 years between
these studies, the broad trend would still likely hold true.
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With respect to MAT-based SAT programming in particular, our study
revealed 20% implementation of any MAT (MTD, BPN, or NTX) and 15.7% of
respondents indicating that they provide methadone, results which are discordant
with the two past studies to look at MAT availability in the correctional setting.
The study by Nunn, et al reported that 55% of state prison administrators stated
that methadone was provided in their facilities. Over half of these facilities further
indicated that methadone was solely used for acute withdrawal management, as
pain medication, or for pregnant women, a ratio somewhat closer to that which
was observed in this study. Our results, obtained largely from units instead of
state agencies and from a wider array of facility types, indicate that methadone is
far scarcer than what is indicated by Nunn, et al.(62) This may indicate a gap
between stated policy on MAT availability and actual practice “on the ground.”
Additionally, this study only had one respondent per state and response bias may
have influenced the findings as respondents were easily identifiable.
Friedmann, et al also noted a much higher use rate of MAT (83% in both
jails and prisons) for opioid withdrawal.(75) However, this definition included
clonidine to alleviate opioid withdrawal symptoms. When focusing more
particularly on opioid replacements (MTD or BPN), the study by Friedmann found
that roughly 50% of jails and prisons reported implementing methadone or
buprenorphine and that fully 25% of each reported policies of continuing opioid
replacement therapy if an individual entered their facility in a treatment program –
about twice the rate of MAT for opioid-related therapy as found in our study. One
mitigating factor is that Friedmann’s study population was drawn from a select
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group of correctional agencies using the CJ-DATS study group. This group tends
to be associated with academic centers and is likely to be more oriented to
evidence-based practice than the broad, national sample that we drew from. This
population is also more skewed to the Northeast and may not include units from
less MAT-friendly parts of the country. Of note, the Friedmann study did not
comment on the geographic origin of their respondents.
Neither these two studies nor our study indicates adequate MAT
implementation, however. Given the longstanding and desperate need for
measures that reduce the population of imprisoned drug users, the lethal danger
of overdose in the population of drug-dependent releasees(18), and the cost to
society of untreated chemical dependency, the continued lack of availability of
this evidence-based treatment is disappointing. The trend towards a lack of EBP
in correctional settings is, unfortunately, common. Friedmann, et al reported a
similar lack of evidence-based practice in their 2006 article, which analyzed the
National Criminal Justice Treatment Protocol (NCJTP) database searching for
EBP. They found that corrections-based drug abuse programming, when in
place, was on average <60% evidence-based practice.
There is reason to believe that concerted efforts geared towards systemic
change can alter the constellation of services available to inmates, however.
Mumola reported that between 1997 and 2004, the number of inmates receiving
any drug treatment in federal prisons had nearly doubled.(76) During this period,
a call to action had been taken up and pressure on correctional agencies to
provide some form of treatment had begun to coalesce. It is reasonable to hope,
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then, that efforts at raising the call for increased uptake of evidence-based
treatment in the correctional system will result in substantive change, albeit
perhaps slowly.

Bias Towards Counseling-Based Treatment Programming
In this study, the correctional system’s tendency to prefer counselingbased treatments is evident. While these do constitute some of the EBP that
have been studied in correctional populations, there continues to be resistance to
MAT-based programming, despite solid evidence for its use. Conversely, rates of
implementation of counseling-based programs are high and the resistance to
implementing future counseling-based treatment is low nationally and across
facility types. Studies by Friedmann and Taxman, both using the NCJTP
instrument, and this author’s literature review for this work indicate that the
correctional literature largely focuses on 12-step programming, Therapeutic
Communities, and case management for SA treatment.(25, 61) While evidence
does support the effectiveness of some of these counseling-based treatments in
correctional systems (though not 12-step programming, the most commonly
available “treatment”), community-based studies of SA treatment consistently
show that MAT is superior across a range of treatment outcomes. This generally
indicates a trend that is seen further in this study that there is currently greater
favor given to counseling-based programming and a lack of willingness to even
consider MAT. This trend may be visible when respondents were asked to
consider the possibility of implementing MAT alone or with counseling.
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Respondents were more likely to be willing to consider MAT with accompanying
counseling than MAT alone. Whether this is because of an understanding of the
evidence in the literature supporting MAT with counseling over MAT alone was
not possible to determine.

Differences Across Facility Types
Interestingly, the use of MAT in corrections appears to be partially
explained by the kind of facility within the correctional system in which treatment
is being provided. Generally speaking, jails hold individuals for a shorter period of
time (anywhere from hours to weeks or a few months) than prisons (usually for
sentences on the order of many months to years) and are the location of the
initial contact that an offender has with the system. In the jail setting, then, there
is more likelihood that an individual would go through withdrawal or be dropped
from their maintenance therapy (if they are enrolled in an opioid replacement
therapy program) compared to the prison setting. Jail administrators thus see a
unique pressure to provide MAT that prisons lack.
In prison, individuals have often been “detoxed” at the jail level before
sentencing, and thus there is very little perceived need to provide maintenance
therapy. Community corrections units often receive individuals once they have
been released on parole from a prison sentence and so in this regard, they see
somewhat of a similar population as that seen in prisons. Community corrections
agencies also monitor those on probation, an alternative to prison, but in the
absence of continuation of methadone therapy in the local jail, individuals
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released to probation are also often not maintained on MAT, having been
detoxed in jail. This is borne out in our results in which a most of the respondents
who indicated that they do not have individuals who would benefit from MAT
were community corrections respondents.
Thus, jails are the only units that receive individuals who are either
currently physically addicted to a substance or maintained on a dose of MTD or
BPN. This is borne out in the distribution of MAT and in the univariate analysis.
The fact that attitudes towards methadone are higher amongst those
administrators responding from a jail may indicate that more familiarity with MAT
results in more positive feelings about its potential usefulness. Similar to the bias
towards counseling-based treatment in the majority of the sample, these results
point to the fact that as an institution becomes familiar with a mode of treatment,
their comfort increases and their attitudes become more positive.
Friedmann, et al(75) and Taxman(25) did find similar absence of MAT in
community corrections environments. Friedmann found greater presence of MAT
in prisons than our study found, however, in a proportion equaling that of jails.
They also did find that prison-based respondents indicate that they prefer drugfree treatment more than jail-based respondents, which tends to be in keeping
with our findings that jails appear more open to MAT-based programming.(75)
Of note, the same study by Friedmann found that there was no difference
across facility types regarding openness to considering MAT-based
programming. Our study found a similarly common level of openness to MAT
across facility types, indicating that while the institutional pressures on each kind
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of facility and the current distribution appears different, all correctional facility
administrators view some role for MAT-based programming. This is an easilymissed but important result from our study.

Regional Differences
One particularly interesting trend in the data is regional variation that runs
throughout. This is first noticeable in the response rate from each region, which
strongly favors the Midwest. The Southeast was less likely to provide any MAT,
while the Northwest and Northeast, on the other hand, were both more likely to
provide MAT than other regions. The 2009 survey by Nunn, et al notes a similar
regional difference in methadone and buprenorphine availability.(62) Additionally,
a majority of respondents in all other regions other than the Southeast were
willing to consider providing MAT if they didn’t already provide it.
When willingness to provide MAT was parsed by particular program, it
appeared that respondents in the Northwest were more willing to provide MAT for
opioid maintenance therapy without counseling, but that this difference lessened
if counseling were added to the programming (perhaps further evidence that
respondents are more comfortable with counseling than with MAT alone).
Respondents from the Southeast, however, stated opposition to any MAT-based
treatment programming. This trend is borne out into the univariate regression
analysis in which region is a significant, albeit minor, predictor of positive stance
towards MAT (either current or potential future implementation). Interestingly,
Southeastern respondents also indicated the highest percentage of those
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reporting recent program expansion. Of note, neither Taxman nor Friedmann’s
work stratified responses by region.
The strength of this pattern may point to the effects of a regional
difference in drug use patterns that drives local treatment patterns. Some areas
of the country have lower heroin and prescription opioid addiction rates
compared to other drugs of abuse (cocaine, methamphetamine, alcohol, etc).
However, very few respondents indicated that their facilities do not have
individuals who would benefit from MAT and these responses were evenly
spread across regions. Thus, this is an unlikely explanation for the variation
seen.
Simply by offering a treatment, institutions may become more comfortable
with it and be more open to using it in the future. These regional patterns may
indicate that respondents in the Southeast have not reached the same level of
comfort with or knowledge about MAT simply because of the fact that this
treatment is not used in this region. A number of respondents noted on the
returned survey forms that they do not provide methadone simply because it has
not been a part of programming in the past. This trend may change if education
or pilot programs are implemented locally that alter local levels of awareness
about how MAT works.
This regional trend may also be reflected in the regional skew seen in the
landmark studies and policy interventions utilizing MAT in the correctional setting.
The studies by Kinlock, et al were performed in Baltimore, Magura’s work was
done at Riker’s Island in New York, and Dolan’s work was done in Australia.
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California, Washington, New York and Arizona are the states most notable for
taking progressive stances towards drug abuse treatment in correctional
settings.(15, 49, 77, 78) The Southeast, then, may simply have less exposure to
MAT as a treatment possibility. Even though region was not found to be a
significant covariate in multivariate analysis, an understanding of which regions
of the country are in most need of intervention to encourage evidence-based
SAT will help those seeking to encourage that change focus their efforts on areas
with the greatest need. As exposure to MAT increases, knowledge about it and
attitudes towards it may also change.

Differing Role of Funding
Our initial hypothesis was that funding would stand as the most significant
contributor to changes in treatment implementation. Our study was done in the
context of a massive economic downturn with accompanying budget cuts all
around the country in state budgets as well as in correctional systems’ substance
abuse treatment services (including the defunding of Proposition 36 in
California). (79) These cuts have decimated state-funded SAT programming. In
the wake of cuts in California, one insider noted, “I think that policy makers now
understand the cost benefits of treatment, but are trying to cope with a massive
short term deficit.” (79)
In keeping with this empiric understanding, in our survey, funding
availability was reported as the greatest contributor to program closure and
decrease, and was viewed as the most important potential barrier to future
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treatment. When respondents who reported program increase were asked to
rank possible contributors to that increase, funding was less important than
offender need and equally important as leadership attitudes. This indicates the
complex nature of funding as a contributor to programming. Empirically, this
makes sense: if money disappears, a program must close, regardless of how
much it may be needed; if leadership at an institutional level demands
programming, available funds may be shifted towards this new priority, thus
causing expansion. Population pressure on the system, as measured by the
responses, “excess offenders requiring treatment” and “recidivism reduction,”
puts pressure on leadership to promote effective ways of reducing inmate
populations. Substance abuse treatment and diversion are proven methods of
accomplishing this aim, and likely contribute to the attitudes of leadership
towards instituting more treatment programming. In this way, funding is a
necessary ingredient to program implementation, but not the only one.
In both univariate and multivariate analysis, size of budget and amount of
budget allocated to SA treatment were not significantly associated with MAT
implementation or willingness to implement MAT. Interestingly, SA budget flux
was predictive of both in univariate analysis: SA budget decrease was predictive
of current MAT implementation and SA budget increase was predictive of current
implementation of or willingness to implement MAT. In multivariate analysis, SA
budget increase remained a significant predictor of MAT implementation and
willingness to implement MAT, along with respondent attitudes towards MAT.
This relationship suggests that the above hypothesis is true: with increased
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funding and positive administrator attitudes, the possibility of implementing MAT
becomes greater.
Notably, this relationship doesn’t hold through when looking at the
influence of SA-specific budget increase on current MAT treatment
implementation. This is likely due to insufficient response (so few respondents
had both a recent increase in SA funding and currently provide MAT). It is
possible also that the level of SA funding currently available is still too low to
sufficiently encourage MAT implementation, pointing to the need to increase SAspecific funding, and specifically for evidence-based treatment.
For as big of a problem as substance abuse is, very little of respondents’
budget is set aside specifically for SAT (median fraction dedicated to SAT was
0.4% of the total budget; Table 1). Empirically, this is likely because correctional
institutions often place SAT programming within another part of the budget –
most commonly, it falls under medical or inmate programming. A simple
intervention to protect SAT programming and to raise its profile within
correctional institutions may be to create an explicit line of an agency’s budget for
it. The import of a suggest that this activity of setting aside SA treatment-specific
funds is vital to contributing to an environment in which administrators feel
comfortable considering MAT implementation.
None of the three other recent major surveys covering SAT in the
correctional setting look at actual funding levels for substance abuse treatment.
The NCJTP- based studies (Taxman, 2007 and Friedmann, 2006) queries
respondents’ attitudes towards current funding levels for programming, but does
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not ask for dollar amounts separate from administrator attitudes. This entangles
the coexistent possibilities that an administrator may have insufficient funds and
believe them to be enough (because of a bias against SAT in correctional
settings) or for an administrator to view comparatively ample funding skeptically.
By separating these variables, our survey achieves a higher degree of specificity
with regards to the role of funding. The survey by Nunn, et al did not publish any
funding-related factors.

Role of Attitudes in MAT Implementation
Contrary to our hypothesis, the most significant contributor to current MAT
implementation is respondent attitude towards methadone. This finding is in
keeping with the general pattern that appears in our data: funding appears to be
an important factor insofar as it is a necessary ingredient to program existence.
Once funding is in hand, the preferences and attitudes of the administrators
allocating the funding then become more important predictors of the shape that
funding actually takes.
Scores on the attitudes scale were also found to be collinear with scores
on the knowledge scale, suggesting this may be the reason knowledge was not
predictive of MAT implementation in multivariate regression. In Friedmann’s 2006
study of the implementation of evidence-based practice (EBP) in NCJTPsurveyed units, it was found that attitudes towards EBP were the best predictor of
their implementation. This group also found that knowledge and attitudes trended
together as independent positive predictors of EBP implementation.
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Role of Knowledge
Knowledge about MAT and awareness of the studies around MAT in
corrections has a significant impact on whether respondents would consider
implementing MAT programming in various settings. Our data indicates that there
is a group that is collectively unaware of the studies on MAT. Moreover, if a
respondent reported being unaware of studies on a particular use of MAT in their
population, they were also less likely to report willingness to consider
implementing MAT. Considering lack of knowledge contributes to a negative
stance on MAT, and our finding that there appears to be a cohesive group that is
not aware of the literature on MAT, a simple knowledge dissemination
intervention could be employed, targeted to this group, to effectively alter this.
Friedmann, in his 2006 and 2012 studies, reported important roles for
knowledge in implementation of evidence-based practice.(61, 75) In their 2012
study, his group found that a respondents’ stated lack of knowledge about MAT
was associated with a lack of implementation at that respondent’s facility.
Conversely, in 2006, reported knowledge was reported to be positively correlated
with implementation of EBP. In 2012, they found that stated knowledge about
MAT was the only factor positively associated with an interest in the future
implementation of MAT-based programming. Although “knowledge” as we
measured it did not take as primary a role in predicting this in our study, the colinearity of knowledge and attitudes points to a common pathway and a clear
importance of both knowledge and its influence on attitudes.
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Limitations
The main limitation of this study lies in response rate. As mentioned in the
methods section, response rates of organizations tend to be lower(73), and may
be lower for the above reasons. Furthermore, a large study of surveys conducted
by academic centers (as opposed to private or corporate survey entities)
revealed an average response rate of 55.9% over the years 1975-1995, with a
decline in average response rate over the years (average response rate was
down to 48.4% in 1995). The subset of academic surveys of administrators or of
organizations fared far worse than average with a mean response rate of
36.1%.(80) Considering this, the obtained response rate (54.9%) was
comparatively optimal for studies of its kind. However, 45.1% of those surveyed
did not respond and the possibility of bias in the results obtained is very real.
There are many reasons that response in this study may have been limited.
One major confounding factor in this analysis is that two out of the five
largest state correctional administrations (composing 12.9% of the total random
sample) declined to respond to the survey because of decisions made by the
research review board in each state. Had these large departments contributed a
response, no significant difference in regional response rate would have been
observed, and the total response rate would have reached 67.8%. The inclusion
of responses from these large institutions would also potentially have had
significant effect on the final analysis if their responses differed from other
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respondents’ in their respective regions. Thus, their absence may point to a
significant response bias.
The content of the survey itself may have been an impediment to
response rate. One comment received from many participants was that the
survey itself was too lengthy and time consuming to complete. Many respondents
also noted that it was too wide-ranging for one person to complete – the
expertise of multiple members of an organization would be called upon to give
accurate responses and this resulted in greater strain than anticipated.
We also asked questions that were possibly viewed as possibly
confidential information – we often received incomplete or absent data for our
questions about budgets and substance abuse outlays within them as well as for
our questions about methadone knowledge and attitudes. This is likely a
manifestation of one of the liabilities of organizational surveying identified by
Tomaskovic, et al. As correctional agencies are highly hierarchical, individuals
within them were less likely to be “empowered … to have the authority to
respond” to such questions within our survey.(73) Furthermore, this
organizational restriction on individual empowerment seems to permeate the
overarching structure within which local correctional units operate: many units
declined to respond because they were limited by state structures and some
units’ responses were received as a part of a larger response from an overarching state agency.
Organizational heterogeneity between state correctional agencies and
between the three main kinds of correctional organizations that we surveyed
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made it difficult to obtain responses because the appropriate respondent in each
organization was not analogous across organizations (i.e. the “Director of Inmate
Services” would be the appropriate respondent at one organization where the
“Health Services Manager” would be the appropriate respondent at another
location). In general, this made targeting of the survey difficult and so we relied
on the organization to direct the survey to the appropriate respondent(s) within
their structures. Often, the complexity of our survey was thus an impediment to
receipt of a response; multiple respondents were necessary in many
organizations and this resulted in many surveys “falling through the cracks”
between individuals and certainly contributed to the low response rate.
Budget cuts all around the country in state budgets as well as in
correctional systems’ substance abuse treatment services (including the
defunding of Proposition 36 in California) (79) have decimated state-funded drug
abuse treatment. One commentator on the aftermath of these cuts remarked, “I
think that policy makers now understand the cost benefits of treatment, but are
trying to cope with a massive short term deficit,” (79) indicating that budget
deficits there have overridden the positive gains in knowledge and attitudes that
came with new programming.
This sentiment is reflected in our responses. It also may have played a
role in increasing the difficulty of obtaining responses from our sample. Many of
the respondents had to be emailed and called many times in order to obtain a
response and often, these responses were incomplete. Several large agencies
refused entirely to participate because of staff and resource limitations.
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Other factors may have also influenced response, such as bias for
substance abuse treatment in corrections compared to no treatment. This
possibility is supported by the fact that 100% of respondents said that they feel
that substance abuse treatment programming has a place in the correctional
system, and rated substance abuse treatment in the correctional system as a
9.25/10 in importance. It is possible that potential respondents who feel that
treatment does not belong in the correctional system did not respond and that a
significant proportion of non-respondents would have given a different response.
Given the proven efficacy of and need for substance abuse treatment in
corrections and the strong mandate from national organizations,(66, 67) this
seems less likely, however.

Future Directions
In sum, our research, taken alongside other recent surveys exploring
factors related to the availability of evidence-based practice, points to the
necessity of testing and implementing several simultaneous approaches to
ensconcing the place of EBP in the correctional environment. Firstly, SAT
programming should be preserved as a distinct line in correctional budgets. The
primacy of the issue of substance abuse in correctional populations is a clear
argument for this and our data indicates that SAT-specific funding increases are
independently related to robust treatment programming implementation.
Secondly, an educational program for correctional administrators should
be devised and piloted with the aim of improving attitudes towards MAT and EBP
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based at least in some part in knowledge dissemination. Alongside this should be
a further study of the underlying aspects of positive and negative attitudes, with
the results of these informing interventions. It is well-understood that factual
knowledge itself is often not sufficient to encourage behavioral change and that
providing an experiential understanding of MAT in a correctional setting may
positively contribute to this effort of raising attitudes about MAT. This study of
institutional and individual change would additionally be of broader interest and
applicability to those working towards change in other large, entrenched
organizations.
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Appendix 1: Survey Instrument

86

Key Terms
Substance use disorders – Addiction to or dependence on illegal drugs like opiates (heroin), stimulants
(methamphetamine, cocaine), or legal drugs like alcohol or prescription drugs (oxycontin, valium).
Medication-Assisted Therapy (abbreviated MAT) – Treatment for substance use disorders that centers on
medications. Examples: Buprenorphine, methadone, naltrexone.
Screening – Looking for the possible presence of a Substance Abuse condition BUT not assigning clinical
designations.
Assessment – Performed by a trained, experienced professional resulting in a clinical diagnosis

Section 1: Background Information
Facility Attributes
F1. What is the average daily population of your facility or probation/parole office in 2009?
Please use complete figures from 2009
a. Number of administrators:
b. Total number of staff (include part and full time):
c. Average daily census of inmates:
d. Number of facilities or offices (Circle one) :

1-3

3-5

e. Number of offenders released on parole/probation/supervision for whom your staff are responsible:

F2. What is your ideal maximum capacity?
Please sum the official capacities of all buildings in your system
_____________
F3. What was your total annual operating budget for 2008-09?
Please round to the nearest $1,000
$__________

F4a. What is the dollar amount of your annual operating budget in 2008-09 that was allocated specifically for treatment
of substance abuse/dependance disorders?
approx $____________
F4b. Since 2006, has this amount:
1. Increased by approximately $____________
2. Decreased by approximately $____________
3. Stayed about the same (Check)



5-7

>7

Section 2: Current Practices
C1. Does your facility currently offer substance abuse treatment services?
(Circle)

Y/N

If yes, continue to question C2. If no, skip to question C5, below
C2. Is there a standardized system by which eligibility for substance abuse treatment services is determined?
(Circle)

Y /N

C3. Is there a standardized system by which referral to treatment is made?
(Circle)

Y /N

C4. Which of the following characteristics influences who gets these services:
a. Severity of the offender’s addiction?
b. Length of stay of the offender?
c. Presence of mental illness?
d. Interest on the part of offenders?
e. Other, indicate:

(Circle)
(Circle)
(Circle)
(Circle)

Y/N
Y/N
Y/N
Y/N

C5. Below is a list of common activities between agencies. Please check all activities that apply to your working relationship with
treatment programs, the judiciary, and other criminal justice agencies on issues specific to offender substance abuse treatment.
(Check  all that apply for each row)

Substance abuse
treatment programs

Judiciary

Jail/prison or community
corrections

a.

We share information on offender needs for
treatment services

1

2

3

b.

Our organizations have agreed to similar
requirements for program eligibility for some
programs

1

2

3

c.

We have written agreements providing space
for substance abuse services for some
programs

1

2

3

d.

We hold joint staffings/case reporting
consultations

1

2

3

e.

We have developed joint policy and procedure
manuals

1

2

3

f.

Our organizations have pooled funding for
some offender substance abuse services

1

2

3

g.

We have modified some program/service
protocols to meet the needs of each agency

1

2

3

h.

We share budgetary oversight of some
treatment programs

1

2

3

i.

We share operational oversight of some
treatment programs

1

2

3

j.

Our organizations cross-train staff on
substance abuse issues

1

2

3

k.

We have written protocols for sharing offender
information

1

2

3

C6. Do you currently provide methadone maintenance therapy for offenders who meet criteria for opioid
dependence: (Circle)

Y / N

If yes, please go on to question C7. If no, please skip to question C9a, below.
C7. How many offenders per year receive methadone maintenance? ___________
C8a. Are you generally satisfied with methadone treatment?

(Circle)

Y / N

C8b. Does your organization have substance abuse treatment-related performance-based contracting in place?
(Circle)

Y / N

C8c. Does your organization receive free methadone in exchange for providing services?

(Circle)

Y / N

C8d. Are there guaranteed slots in community clinics that are set aside for individuals treated with methadone
maintenance in your system?

(Circle)

Y / N

Please indicate which of the following apply to why you don’t provide methadone maintenance therapy:
C9a. There are not offenders in our system who have been dependent on opioids (heroin, prescription pain
killers, methadone)

(Circle)

Y/N

C9b. Licensing regulations to prescribe methadone are too costly (Circle)

Y/N

C9c. Methadone is too highly regulated and thus providing it would be very difficult (Circle)
C9d. Methadone would be too easily diverted and abused within our system

(Circle)

Y/N

Y/N

C10. Do you currently provide buprenorphine (BPN) treatment for offenders who meet criteria for opioid
dependence:

(Circle)

Y / N

If yes, please go on to question C11. If no, please skip to question C13a, below.
C11. How many offenders per year receive buprenorphine (BPN) ___________
C12a. Are you generally satisfied with BPN treatment?

(Circle)

Y / N

C12b. Does your organization have substance abuse treatment-related performance-based contracting in place?
(Circle)

Y / N

C12c. Does your organization receive free buprenorphine in exchange for providing services? (Circle)

Y / N

C12d. Are there guaranteed slots in community clinics that are set aside for individuals treated with BPN in
your system? (Circle)

Y / N

Please indicate which of the following apply to why you don’t provide BPN:
C13a.

There are not offenders in our facilities who have been dependent on opioids (heroin, prescription pain
killers, methadone) (Circle)

Y/N

C13b.

Licensing regulations to prescribe BPN are too costly (Circle)

C13c.

BPN is too highly regulated and thus providing it would be very difficult (Circle)

C13d.

BPN would be too easily diverted and abused within our system

Y/N
(Circle)

Y/N

Y/N

C14. Do you currently provide naltrexone treatment for offenders who meet criteria for alcohol dependence:
(Circle)

Y / N

If yes, please go on to question C15. If no, please skip to question C17a, below.
C15. How many offenders per year receive naltrexone in the:
a. Oral Form (ReVia) _________

b. Injectable Form (Vivitrol)_________

C16a. Are you generally satisfied with naltrexone treatment?

(Circle)

Y / N

C16b. Does your organization have substance abuse treatment-related performance-based contracting in place?
(Circle)

Y / N

C16c. Does your organization receive free naltrexone in exchange for providing services?

(Circle)

Y / N

C16d. Are there guaranteed slots in community clinics that are set aside for individuals treated with
naltrexone in your system?

(Circle)

Y / N

If no, please briefly describe why you don’t provide naltrexone:
C17a.

Cost of drug is prohibitive

C17b.

Personnel limitations (needs to be given by medical staff)

C17c.

Other ________________________________________

(Circle)

Y/N
(Circle)

Y/N

C18. By your estimation, have there been any significant change in staffing levels recently within your correctional
system?
(Circle)

Y / N

(If yes, continue to C19. If no, skip to question C20)
C19. Please check the appropriate box next to each staff type
Staffing type

Increased

Unchanged

Decreased

a. Administrative staff—management

2

1

0

b. Administrative staff—support

2

1

0

c. In your prison/jail facility, corrections/custody/security staff

2

1

0

d. Clinical staff—management

2

1

0

e. Substance abuse assessment staff (who do not do counseling)

2

1

0

f. Substance abuse clinical staff (include assessors if they also do counseling)

2

1

0

2

1

0

2

1

0

g. Other clinical staff (social workers, vocational or mental health
counselors, etc.)
h. Case managers/resource brokers

C20. In the past two years, have any substance abuse treatment programs in your organization...
Please  all that apply
2 Been closed? 1 Had treatment beds or slots reduced?
If neither, skip to question 23

0 Neither

C21. If there has been a reduction, identify up to three factors that contributed most to the reduction
Choose up to three factors from the list below

1
2

Funding cuts due to state deficit or other budget problems
Low offender buy-in for drug treatment programs

3
4
5

Failure of programs to achieve success

6
7
8

Leadership dissatisfaction with treatment program(s)

New legislation/policy prevented further use of treatment
Too many offenders with mental health problems

Not enough offenders eligible for program(s)
Offenders not in facility long enough to justify treatment

9 Offenders in facility for too long to justify treatment; use detoxification instead
10 Prefer drug-free method over MAT
11 No proof that MAT works in your population of offenders
12
13
14

Released individuals with substance abuse/dependence in prison to the community to save costs on treatment
Insufficient space for treatment programs
Other (specify)_____________________

C22. With the factors listed above in question C21 in mind, please rank them using the scale below to indicate their influence
on your programming.
1 – Presents a major problem
2 – Presents a minor problem
3 – Presents no problem at all
4 – Can’t say either way
Factor

Rank

a. Funding cuts due to state deficit or other budget problems
b. Low offender buy-in for drug treatment programs
c. Failure of programs to achieve success
d. New legislation/policy prevented further use of treatment
e. Too many offenders with mental health problems
f. Leadership dissatisfaction with the treatment program
g. Not enough offenders eligible for the program
h. Offenders not in facility long enough to justify treatment
i. Offenders in facility for too long to justify treatment; use detoxification instead
j. Prefer drug-free method over MAT
k. No proof that MAT works in your population
l. Released individuals with substance abuse/dependence in prison to the community to
save costs on treatment
m. Insufficient space for treatment programs
n. Other (specify)_____________________

C23. In the past two years, have any substance abuse treatment programs in your organization...

(  all that apply)
2 Been opened?

1 Had treatment beds or slots increased?

0

Neither

If neither, skip to question 23
C24. If so, identify up to three factors that contributed most to programs being opened or increased:
Check next to up to three factors on the list below

1

New funding from federal agencies

2 New funding from state government
3 Positive attitude of correctional staff toward treatment programs
4 Excess number of offenders needing treatment services
5 New leadership that supports the expansion of treatment
6 Realization that treatment can reduce recidivism
7 Other (specify)____________________
C25. With the factors listed above in question C24 in mind, please rank them using the scale below to indicate their influence
on your programming.
1 – Major contributor to increase
2 – Minor contributor to increase
3 – Not a contributor to increase
4 – Can’t say either way
Factor
New funding from federal agencies

Rank

New funding from state government
Positive attitude of correctional staff toward treatment programs
Excess number of offenders needing treatment services
New leadership that supports the expansion of treatment
Realization that treatment can reduce recidivism
Other (specify)_____________________

Section 3: Perspectives About Current and Future Substance Abuse Treatment
P1. How would you assess the following potential barriers to implementing new programs/policies focused on
substance dependent offenders?
Please rank the barriers below in order of impact on your ability to implement new programming. When ranking, please
choose only one rank (along the top) per barrier (listed down the left-hand column).
Please fully check one box. Please do not check between boxes.

a. Qualified staff
b. Funding
c. Leadership philosophy

No barrier

Slight barrier

Moderate barrier

Significant barrier

0
0
0

1
1
1

2
2
2

3
3
3

No barrier

Slight barrier

Moderate barrier

Significant barrier

0
0
0
0
0

d. Staff attitudes
e. Public attitudes
f. Organizational capacity
g. Physical space
h. Other (Please specify) ________________

1
1
1
1
1

2
2
2
2
2

3
3
3
3
3

P2. Given the list of programs below, which barriers would present a major obstacle to implementation of new
programs/policies focused on substance dependent offenders in your organization?

c. Group counseling

 

d. Medication to treat withdrawal

 

e. Medication to provide maintenance
therapy

 

f. Medication to treat alcohol dependence

 

g. Medication to treat cocaine dependence

 

h. Medications plus counseling

 

1

1

1

1

1

1

1

2

2

2

2

2

2

2

No barrier exists

5

6

7

8



3

4

5

6

7

8



3

4

5

6

7

8



3

4

5

6

7

8



3

4

5

6

7

8



3

4

5

6

7

8



3

4

5

6

7

8



3

4

5

6

7

8



____________

4

____________

3

Other
(Please specify)

Physical
space

 

2

Organizational
capacity

b. Individual counseling

1

Public
attitudes

 

Staff
attitudes

Funding

a. Narcotics or
Alcoholics
Anonymous

Leadership
philosophy

Programs

Qualified staff

Barriers to
Implementation

Please  the box next to each of the program types (listed in the left-most column) and underneath the appropriate existing
barrier(s) (listed across the top).
Mark up to three barriers per program. If no barrier exists, please indicate that by checking the box under No barrier exists

0

0

0

0

0

0

0

0

P3. If all barriers to doing so were removed, would you like to add new treatment programs or increase capacity for substance
dependent offenders in your facility?

 Yes

 No

If no, please skip to question P5

P4. What goals would you be satisfying if you were to implement new treatment programs for substance

dependent offenders?
Understanding that each item is important, please rank the choices in order of priority from 1 (highest) to 5 (lowest). We want to know
which of the goals holds most importance for your organization. Please only assign one rank per choice.
a. Reduced recidivism in your jurisdiction ___
b. Reduced substance use in facility ___
c. Rehabilitation of the offender ___
d. Cost-Effectiveness ___
e. Other (Please specify) ________________________ ___
P5. Now you will be asked to consider a list of possible treatment plans for substance abusing offenders. Indicate
whether you would implement, would consider implementing, or would not implement such a program.
Note: When giving your answers, imagine no restrictions on the possibility of implementing a program/policy.
Please only check one box below the appropriate option corresponding to each program type.
If you already provide the program, check Already Implemented
Already
Implemented

Would
Implement

Would
consider
implementation

Would not
consider
implementation
currently

c. Group counseling

3
3
3

2
2
2

1
1
1

0
0
0

d. Medication to treat opioid withdrawal (such as
methadone or buprenorphine)

3

2

1

0

e. Medication for opioid maintenance therapy (such as
methadone or buprenorphine)

3

2

1

0

f. Medication to treat alcohol dependence (such as
naltrexone)
g. Medication to treat cocaine dependence (such as
antabuse)
h. Medications (any medications used to treat substance
disorders) plus counseling

3

2

1

0

3

2

1

0

3

2

1

0

Program
a. Narcotics or alcoholics anonymous
b. Individual counseling

P6. Now you will be asked about the effectiveness of a list of possible treatment plans for substance abusing
offenders.
Please rank each program by the 6 point scale in the table below. Please choose only one rank per program type.
Completely
Ineffective

Moderately
ineffective

Slightly
Ineffective

Slightly
Effective

Moderately
Effective

Completely
Effective

d. Medication to treat opioid withdrawal

0
0
0
0

1
1
1
1

2
2
2
2

3
3
3
3

4
4
4
4

5
5
5
5

e. Medication to provide opioid
maintenance therapy

0

1

2

3

4

5

f. Medication to treat alcohol dependence

0
0
0

1
1
1

2
2
2

3
3
3

4
4
4

5
5
5

Program
a. Narcotics or alcoholics anonymous
b. Individual counseling
c. Group counseling

g. Medication to treat cocaine dependence
h. Medications plus counseling

P7. Now you will be asked to consider what has been shown by studies on each of these programs that have been performed in
the population you work with.
Please check next to each program under the descriptive category that best fits it. Please check one description per program.
Program

Shown to work

Shown not to
work

Studies
inconclusive

Not sure of
studies

3
3
3
3
3
3
3
3

2
2
2
2
2
2
2
2

1
1
1
1
1
1
1
1

0
0
0
0
0
0
0
0

a. Narcotics or alcoholics anonymous
b. Individual counseling
c. Group counseling
d. Medication to treat opioid withdrawal
e. Medication to provide opioid maintenance therapy
f. Medication to treat alcohol dependence
g. Medication to treat cocaine dependence
h. Medications plus counseling

P8. This series of questions has to do with how you view methadone in particular. Please answer each question
with a “yes” or “no” based on your feelings about methadone.
Please  Y / N
Y

N

a. Staff will restrict access to methadone to control offenders.





b. No matter how many safeguards there are, offenders who aren’t supposed to receive methadone will get it.





c. The safeguards built into the methadone program are adequate to prevent illicit use.





d. The methadone program will increase medical problems.





e. A methadone program will lead to fewer offender infractions.





f. The potential for offender abuse outweighs the potential benefit of the methadone program.





g. The methadone program will increase security risks.





h. Heroin addicts should just quit. It doesn’t make much sense to use methadone.





i. The way methadone is dispensed is so restricted that it’s not worth using.





j. I admire people who join a methadone program to kick their heroin habit.





k. I admire people who kick their heroin habit.





l. The final goal of methadone treatment should be abstinence from all drugs.





m. Methadone treatment substitutes one addictive drug for another.





n. Making people go through withdrawal will teach them a lesson.





o. It is not worth the money to use methadone; people will use drugs if they want to.





P9. The following questions are in regards to methadone as a treatment. Please answer each question with a
“yes” or “no” based on what you know about methadone.
Please  Y / N
Y

N

a. Heroin addicts on methadone die at a younger age than people on heroin





b. Methadone causes bone and tooth decay.





Y

N

c. Longer periods of methadone maintenance are better than shorter periods for preventing relapse.





d. Methadone clients should not be allowed to operate heavy machinery or to drive a car.





e. A maintenance dose of methadone gets people high.





f. Methadone can treat alcohol and cocaine as well as heroin addiction.





g. Heroin addiction is a moral weakness.





h. Methadone can only be used safely for a short time.





i. Heroin addiction is a disease.





j. A methadone dose should be high enough to prevent withdrawal symptoms.





k. People on methadone are too ‘‘zoned out’’ to work.





l. When a woman on methadone becomes pregnant she should quit using it.





m. Methadone is a drug that can be used for getting high.





n. Methadone is the best treatment for heroin.





o. You should use the lowest possible dose of methadone (for maintenance) or other dosing issues.





P10. On a scale of 1 (unimportant) to 10 (very important), rate the importance of providing
substance abuse treatment to offenders with substance abuse problems...
Write a number 1-10 on the line below
a. In prison ______

b. In the community ______

c. In prison and the community simultaneously _______

P11a. Do you feel the corrections system should have a role in screening and treatment for substance abuse problems?
(Circle)

Y / N

P11b. Please briefly describe your answer 

Thank you for your time and careful consideration of our questions. Your help is greatly appreciated in our efforts to
advance the health of our nation and its citizens.
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